focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Deja vu
With some Erroxon built in.
Surely worth Billions.
Not that they want to do that obviously.
We’re Lombard making sure they stayed below 29%.? If you hit that amount haven't you got to state whether you are in takeover mode?
So now holding 28.5%?
You reckon they will go into specifics around sales figures as the sales data ultimately belongs to their distribution partners ? Bit hard to present at an investors seminar and not share specifics around sales progress to date (numbers)
Will be interesting what is said this Friday as I’m guessing the words ‘selling well’ will not wash! Anybody attending or know what information will probably be released? Guessing if there is any frantic buying we will be able to guess!
Personally not bothered at all by the reporting mistake. these things do happen. far more interesting is the fact that LO have significantly increased their percentage holding by over 2.5%. strong vote of confidence imo. obviously we don't know what they may do over the course of time, but as we speak it seems extremely positive.
lol isnt it obvious.... i assume they reduce their holding and exercise the warrants it to keep it the same?
that or that is a massive **** up
Looks like a mis-communication had them confused. Between the RNS on 24th April and the one on the 16th June, Lombard reduced their holding from 74,913,591 to 74,308,479. But then you add on the 10,937,500 warrants and you get today's total of 85,245,979. So the breakdown in comms was around the reduction before the warrants got added. Lombard obviously expected one RNS to just show the new total but the company RNS'd the reduction pre-warrants by accident.
It’s ridiculous
I agree how did they get this wrong. We all know they just got 10 mil new shares from the warrants. So I personally didn't understand how they said they had reduced their holdings.
Let's hope they aren't in a hurry to sell the extra 10 mil as that will hold back the share price imo
How can these guys get this so wrong? Now it suggest that LO have been accumulating.
Doh! yes ignore me, most of you do probably anyway LOL
Can't believe I posted that yes of course was removed after trials in order to obtain medical device status, doh! something to do with being busy at work, & rushing emails out on here. Yes the whole point was no active ingredients, hence OTC
5000 in the last month, 2000 of that 5000 in the last week. Gathering apace.
Thanks for linking that article....I didn't think it was bad at all and I would have thought most people with a brain can see the reviews are dodgy, many repeat the same few words and there are a silly number of up and down ticks, totally OTT. Potential buyers are more likely to make their decision based on the official 60% clinical trials number.
Interesting article, FUM have never in my opinion been forthcoming with all the facts. But you have to ask yourself, would Coopers have committed to such an enormous investment in Eroxon without scrutinising all the data, I very much doubt it, they are no mugs and that speaks volumes in itself.
I think this is a 50/50 review in The Washington Post, of Eroxon chances of success.
I wish i had left more positive reviews on The Boots webpage, as they've been noted by the WP and a link posted.
I suppose the Boots reviews have now also been seen by 1000's of potential new U.S customers too..
https://www.washingtonpost.com/wellness/2023/06/15/eroxon-erectile-dysfunction-treatment/
Well done LB you're probably dancing like a madman in your mums basement right now.
The.Italian. Bucolic. Thanks, and yes, exactly.
And any chemist will tell you very quickly that Glycerin/glycerol is very different to compound nitrates of the substance.
Perhaps someone can help.
In the RNS of 20th Dec 2019 regarding a fundraise at 8p it says LO will be ararded up to 20.312m warrants to be exercised at 40p.
In the RNS of 23rd Dec 2019 it says LO have been awarded 10,937,500 warrants to be exercised at 40p
I had assumed there were stil 9m warrants still to come but it looks like the warants of 10m have been exercised and there are no more to come.
Perhaps somebody can ask for this to be cleared up at the investor seminar.
If there are no more warrants in the background then onwards and upwards even faster.
Morning bucolic.perfectly correct.it does seem as though retaining the name has caused some genuine confusion,but the current position is really very clear.
Come on, Chizz, get with the program! MED2005 contained GTN, but failed P3 because the placebo, Dermasys, had such a high score. So FUM changed course, and Dermasys became MED3000 without GTN. As I said yesterday, they should have changed the name from Eroxon to avoid all this confusion.
Eroxon does not contain GTN. that is the whole rationale behind fum being able to pursue the medical device route.see the RNS of 19th dec 2019 for example.
Weareallguessing
Eroxon has glycerine in the ingredients, there is no chemical difference between glycerol, glycerin or glycerine. All 3 names refer to the same compound, propane-1,2,3-triol. similar to anitbiotics having different brand names but the same drug. GTN refers to Glyceryl trinitrate, also part of that same family.
Early research showed using this drug on heart patients basically gave a boner! hence the research & the use of it in Eroxon.
If you research the above you will find this to be correct. I've researched everything about this product over 10 years, & believe this to be correct. There are many reports online stating that Eroxon has this ingredients in it. Doubtful they are all wrong,
Yes, it’s starting to firm up nicely.
A continuous upward trend is in place.
MCap of £125M for Global rollout of this product is a pittance. Imagine what Global Sales could be.